AMRX logo

Amneal Pharmaceuticals, Inc. (AMRX) Cash From Financing

Annual CFF:

-$211.72M-$161.56M(-322.11%)
December 31, 2024

Summary

  • As of today, AMRX annual cash from financing is -$211.72 million, with the most recent change of -$161.56 million (-322.11%) on December 31, 2024.
  • During the last 3 years, AMRX annual cash from financing has fallen by -$73.60 million (-53.28%).
  • AMRX annual cash from financing is now -140.61% below its all-time high of $521.39 million, reached on December 1, 2015.

Performance

AMRX Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherAMRXcash flow metrics

Quarterly CFF:

-$41.69M-$2.52M(-6.44%)
June 30, 2025

Summary

  • As of today, AMRX quarterly cash from financing is -$41.69 million, with the most recent change of -$2.52 million (-6.44%) on June 30, 2025.
  • Over the past year, AMRX quarterly cash from financing has dropped by -$6.60 million (-18.81%).
  • AMRX quarterly cash from financing is now -108.91% below its all-time high of $467.98 million, reached on March 31, 2020.

Performance

AMRX Quarterly Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherAMRXcash flow metrics

TTM CFF:

-$234.33M-$6.60M(-2.90%)
June 30, 2025

Summary

  • As of today, AMRX TTM cash from financing is -$234.33 million, with the most recent change of -$6.60 million (-2.90%) on June 30, 2025.
  • Over the past year, AMRX TTM cash from financing has dropped by -$151.09 million (-181.50%).
  • AMRX TTM cash from financing is now -144.70% below its all-time high of $524.24 million, reached on September 1, 2015.

Performance

AMRX TTM Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherAMRXcash flow metrics

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

AMRX Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year-322.1%-18.8%-181.5%
3Y3 Years-53.3%-100.9%-108.8%
5Y5 Years-400.6%+86.6%-268.5%

AMRX Cash From Financing Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-322.1%at low-168.3%+54.9%-367.2%at low
5Y5-Year-256.7%at low-168.3%+54.9%-268.5%+34.7%
All-TimeAll-Time-140.6%at low-108.9%+86.6%-144.7%+34.7%

AMRX Cash From Financing History

DateAnnualQuarterlyTTM
Jun 2025
-
-$41.69M(-6.4%)
-$234.33M(-2.9%)
Mar 2025
-
-$39.17M(+35.9%)
-$227.73M(-7.6%)
Dec 2024
-$211.72M(-322.1%)
-$61.13M(+33.8%)
-$211.72M(-136.4%)
Sep 2024
-
-$92.35M(-163.2%)
-$89.55M(-7.6%)
Jun 2024
-
-$35.09M(-51.5%)
-$83.24M(-37.8%)
Mar 2024
-
-$23.16M(-137.9%)
-$60.41M(-20.4%)
Dec 2023
-$50.16M(+51.4%)
$61.04M(+170.9%)
-$50.16M(+61.9%)
Sep 2023
-
-$86.04M(-602.0%)
-$131.64M(-43.5%)
Jun 2023
-
-$12.26M(+5.0%)
-$91.73M(+8.5%)
Mar 2023
-
-$12.90M(+36.9%)
-$100.23M(+4.5%)
Dec 2022
-$103.23M(+25.3%)
-$20.45M(+55.7%)
-$104.90M(+8.6%)
Sep 2022
-
-$46.13M(-122.3%)
-$114.80M(-2.3%)
Jun 2022
-
-$20.75M(-18.1%)
-$112.23M(+13.4%)
Mar 2022
-
-$17.57M(+42.1%)
-$129.54M(+6.2%)
Dec 2021
-$138.12M(-202.2%)
-$30.35M(+30.3%)
-$138.12M(-16.0%)
Sep 2021
-
-$43.55M(-14.4%)
-$119.05M(-36.8%)
Jun 2021
-
-$38.07M(-45.6%)
-$87.01M(+75.8%)
Mar 2021
-
-$26.15M(-131.8%)
-$359.02M(-365.7%)
Dec 2020
$135.11M(+419.5%)
-$11.28M(+2.0%)
$135.11M(-2.9%)
Sep 2020
-
-$11.51M(+96.3%)
$139.09M(-2.7%)
Jun 2020
-
-$310.08M(-166.3%)
$143.00M(-67.9%)
Mar 2020
-
$467.98M(+6512.4%)
$445.54M(+1153.5%)
Dec 2019
-$42.29M(-114.1%)
-$7.30M(+3.9%)
-$42.29M(+83.3%)
Sep 2019
-
-$7.60M(-0.7%)
-$253.91M(-67.1%)
Jun 2019
-
-$7.54M(+62.0%)
-$151.94M(-148.6%)
Mar 2019
-
-$19.85M(+90.9%)
$312.84M(+4.5%)
Dec 2018
$299.45M(+415.2%)
-$218.92M(-332.0%)
$299.45M(-41.7%)
Sep 2018
-
$94.38M(-79.4%)
$513.84M(+42.4%)
Jun 2018
-
$457.24M(+1475.3%)
$360.72M(+473.7%)
Mar 2018
-
-$33.25M(-633.9%)
-$96.52M(-52.5%)
Dec 2017
-$95.02M(-124.3%)
-$4.53M(+92.3%)
-$63.28M(+2.3%)
Sep 2017
-
-$58.75M(-880.1%)
-$64.74M(-116.5%)
Dec 2016
$391.78M(-24.9%)
-
-
Dec 2016
-
-$5.99M(-101.5%)
$391.78M(-1.7%)
Sep 2016
-
$388.06M(>+9900.0%)
$398.64M(+2312.7%)
Jun 2016
-
$1.61M(-80.1%)
$16.52M(-84.8%)
Mar 2016
-
$8.11M(+835.1%)
$108.60M(-79.2%)
Dec 2015
$521.39M(+3517.2%)
$867.00K(-85.4%)
$521.39M(-0.5%)
Sep 2015
-
$5.94M(-93.7%)
$524.24M(+0.8%)
Jun 2015
-
$93.69M(-77.7%)
$519.83M(+21.3%)
Mar 2015
-
$420.89M(>+9900.0%)
$428.41M(+2872.2%)
Dec 2014
$14.41M(+60.8%)
$3.72M(+142.9%)
$14.41M(+10.6%)
Sep 2014
-
$1.53M(-32.6%)
$13.04M(-2.2%)
Jun 2014
-
$2.27M(-67.1%)
$13.33M(-6.8%)
Mar 2014
-
$6.90M(+195.0%)
$14.31M(+59.7%)
Dec 2013
$8.96M
$2.34M(+28.0%)
$8.96M(+2.3%)
Sep 2013
-
$1.83M(-43.7%)
$8.76M(-36.2%)
Jun 2013
-
$3.25M(+109.3%)
$13.72M(+7.5%)
DateAnnualQuarterlyTTM
Mar 2013
-
$1.55M(-27.3%)
$12.77M(-26.3%)
Dec 2012
$17.32M(-18.7%)
$2.13M(-68.6%)
$17.32M(-2.6%)
Sep 2012
-
$6.79M(+196.1%)
$17.77M(+34.4%)
Jun 2012
-
$2.29M(-62.4%)
$13.23M(-28.1%)
Mar 2012
-
$6.10M(+135.4%)
$18.39M(-13.7%)
Dec 2011
$21.31M(-10.8%)
$2.59M(+15.5%)
$21.31M(-12.5%)
Sep 2011
-
$2.24M(-69.9%)
$24.35M(+4.9%)
Jun 2011
-
$7.45M(-17.4%)
$23.23M(-15.5%)
Mar 2011
-
$9.02M(+60.1%)
$27.49M(+15.0%)
Dec 2010
$23.90M(+416.1%)
$5.64M(+404.6%)
$23.90M(+20.6%)
Sep 2010
-
$1.12M(-90.5%)
$19.81M(+3.5%)
Jun 2010
-
$11.71M(+115.6%)
$19.15M(+889.4%)
Mar 2010
-
$5.43M(+250.5%)
-$2.43M(+67.9%)
Dec 2009
-$7.56M(+88.4%)
$1.55M(+240.7%)
-$7.56M(+17.3%)
Sep 2009
-
$455.00K(+104.6%)
-$9.15M(+86.8%)
Jun 2009
-
-$9.86M(-3410.1%)
-$69.56M(-16.5%)
Mar 2009
-
$298.00K(+927.8%)
-$59.69M(+0.5%)
Dec 2008
-$65.08M(-729.6%)
-$36.00K(+99.9%)
-$59.99M(-0.1%)
Sep 2008
-
-$59.95M(>-9900.0%)
-$59.95M(-157.3%)
Dec 2007
$10.34M(>+9900.0%)
-
-
Dec 2006
-$15.00K(+99.9%)
-
-
Dec 2005
-$29.71M(-202.8%)
-
-
Sep 2004
-
-$125.00K(-100.1%)
$104.65M(+0.6%)
Jun 2004
-
$99.99M(+9616.9%)
$104.06M(+280.3%)
Mar 2004
-
$1.03M(-72.6%)
$27.37M(-5.3%)
Dec 2003
$28.91M(+477.5%)
$3.76M(+626.2%)
$28.91M(+30.1%)
Sep 2003
-
-$715.00K(-103.1%)
$22.22M(-3.0%)
Jun 2003
-
$23.29M(+804.8%)
$22.92M(+528.6%)
Mar 2003
-
$2.57M(+188.0%)
$3.65M(-27.2%)
Dec 2002
$5.01M(-90.1%)
-$2.93M(>-9900.0%)
$5.01M(-66.7%)
Sep 2002
-
-$21.00K(-100.5%)
$15.02M(-17.1%)
Jun 2002
-
$4.02M(+2.2%)
$18.13M(-67.3%)
Mar 2002
-
$3.93M(-44.5%)
$55.44M(+9.4%)
Dec 2001
$50.69M(+61.5%)
$7.09M(+129.9%)
$50.69M(-14.2%)
Sep 2001
-
$3.08M(-92.5%)
$59.07M(+5.0%)
Jun 2001
-
$41.33M(+5177.0%)
$56.26M(+269.4%)
Mar 2001
-
-$814.00K(-105.3%)
$15.23M(-51.5%)
Dec 2000
$31.38M(+144.4%)
$15.47M(+5484.1%)
$31.38M(+30.4%)
Sep 2000
-
$277.00K(-7.7%)
$24.07M(-0.1%)
Jun 2000
-
$300.00K(-98.0%)
$24.10M(-3.7%)
Mar 2000
-
$15.34M(+88.1%)
$25.02M(+94.9%)
Dec 1999
$12.84M(+749.3%)
$8.15M(+2513.8%)
$12.84M(+129.4%)
Sep 1999
-
$312.00K(-74.4%)
$5.60M(-6.7%)
Jun 1999
-
$1.22M(-61.3%)
$6.00M(+26.8%)
Mar 1999
-
$3.15M(+245.7%)
$4.73M(+212.8%)
Dec 1998
$1.51M
$912.00K(+28.1%)
$1.51M(+152.0%)
Sep 1998
-
$712.00K(+1583.3%)
$600.00K(+635.7%)
Jun 1998
-
-$48.00K(+25.0%)
-$112.00K(-75.0%)
Mar 1998
-
-$64.00K
-$64.00K

FAQ

  • What is Amneal Pharmaceuticals, Inc. annual cash from financing?
  • What is the all-time high annual cash from financing for Amneal Pharmaceuticals, Inc.?
  • What is Amneal Pharmaceuticals, Inc. annual cash from financing year-on-year change?
  • What is Amneal Pharmaceuticals, Inc. quarterly cash from financing?
  • What is the all-time high quarterly cash from financing for Amneal Pharmaceuticals, Inc.?
  • What is Amneal Pharmaceuticals, Inc. quarterly cash from financing year-on-year change?
  • What is Amneal Pharmaceuticals, Inc. TTM cash from financing?
  • What is the all-time high TTM cash from financing for Amneal Pharmaceuticals, Inc.?
  • What is Amneal Pharmaceuticals, Inc. TTM cash from financing year-on-year change?

What is Amneal Pharmaceuticals, Inc. annual cash from financing?

The current annual cash from financing of AMRX is -$211.72M

What is the all-time high annual cash from financing for Amneal Pharmaceuticals, Inc.?

Amneal Pharmaceuticals, Inc. all-time high annual cash from financing is $521.39M

What is Amneal Pharmaceuticals, Inc. annual cash from financing year-on-year change?

Over the past year, AMRX annual cash from financing has changed by -$161.56M (-322.11%)

What is Amneal Pharmaceuticals, Inc. quarterly cash from financing?

The current quarterly cash from financing of AMRX is -$41.69M

What is the all-time high quarterly cash from financing for Amneal Pharmaceuticals, Inc.?

Amneal Pharmaceuticals, Inc. all-time high quarterly cash from financing is $467.98M

What is Amneal Pharmaceuticals, Inc. quarterly cash from financing year-on-year change?

Over the past year, AMRX quarterly cash from financing has changed by -$6.60M (-18.81%)

What is Amneal Pharmaceuticals, Inc. TTM cash from financing?

The current TTM cash from financing of AMRX is -$234.33M

What is the all-time high TTM cash from financing for Amneal Pharmaceuticals, Inc.?

Amneal Pharmaceuticals, Inc. all-time high TTM cash from financing is $524.24M

What is Amneal Pharmaceuticals, Inc. TTM cash from financing year-on-year change?

Over the past year, AMRX TTM cash from financing has changed by -$151.09M (-181.50%)
On this page